Dercum’s disease is a rare pain syndrome characterized by chronically painful growths of fatty tissue or lipomas. These lipomas most commonly occur in the upper arms, upper legs, and trunk region. According to a report by the American Society of Interventional Pain Physicians in 2017, although women are most commonly affected by this condition, about 16% of the reported cases were in men. The common symptoms of this condition include painful fatty lipomas covering the body, obesity majorly in women in menopausal age, weakness, memory issues, elevated heart rate, joint aches, depression, and dementia. Currently, there is no cure for this condition and it is treated symptomatically with surgery, alternative therapies, and with medications such as non-steroidal anti-inflammatory drugs, diuretics, among others.
The Dercum’s Disease Market is anticipated to be growing due to factors such increasing expenditures in the healthcare sector in the developed as well as developing economies, growing occurrences of lipomas, increasing prevalence of rare diseases, and rising research and development activities. On the other hand, lack of awareness about the disease is likely to hamper the growth of the market over the forecast period.
The global dercum’s disease market has been segmented into treatment, distribution channel, and end user.
Pfizer, Inc., Abbvie, Inc., Johnson Johnson, GlaxoSmithKline Plc, Merck Co., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, Amgen, Valeant Pharmaceuticals, Syneron Medical, St. Jude Medical Inc. and Alimed, Inc. are some major players in the global dercum’s disease market.
On the regional basis, the dercum’s disease market in the Americas is segmented into two major regions, i.e., North America and South America. The North American region is likely to hold the major share in the global dercum’s disease market, owing to the owing to the presence of a well-established healthcare segment, and increasing disposable income. Moreover, increasing funding for research and development by government fuels the market growth in this region.
Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample request/6350
The global Dercum’s disease market is segmented by treatment, distribution channel, and end-user.
By treatment, it is segmented into acupuncture, surgery, electrotherapy, medication, liposuction, and others. Electrotherapy can show the way for effective treatment for patients with the debilitating disease. Frequency rhythmic electrical modulation system (FREMS) and its subsequent success on administration to patients can drive the segment growth till 2023.
By distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and others.
By end-user, it is segmented into ambulatory surgical centers, hospitals
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Market Research Future®
99 Hudson Street,5Th Floor
New York, New York 10013
United States of America